U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21ClO4
Molecular Weight 360.831
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOFIBRATE

SMILES

CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2

InChI

InChIKey=YMTINGFKWWXKFG-UHFFFAOYSA-N
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25903954

Fenofibrate is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. It’s used as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is a fibric acid derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. Fenofibrate is rapidly hydrolyzed after oral ingestion to its pharmacologically active form, fenofibric acid. The effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII (an inhibitor of lipoprotein lipase activity), which increases lipolysis and elimination of triglyceride-rich particles from plasma. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. PPARα also increases apoproteins AI and AII, reduces VLDL- and LDL-containing apoprotein B, and increases HDL-containing apoprotein AI and AII.Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid. Fenofibrate also has an off-label use as uricosuric therapy in people who have gout.

CNS Activity

Curator's Comment: fenofbrate cannot cross the blood-brain barrier and reach the central nervous system

Originator

Curator's Comment: Procetofen was synthesized in 1974 and was introduced in clinical practice in France the same year. Procetofen, which significantly decreased plasma lipid concentrations in hyperlipidemic patients, was later called fenofibrate to comply with World Health Organization nomenclature guidelines

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
TRICOR

Approved Use

Treatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Launch Date

1.09952644E12
Palliative
TRICOR

Approved Use

Treatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Launch Date

1.09952644E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.96 μg/mL
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.9 μg × h/mL
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.1 h
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
16 h
160 mg 1 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FENOFIBRIC ACID serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
160 mg 1 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FENOFIBRIC ACID serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Other AEs: Asthenia, Pain...
Other AEs:
Asthenia (1.1%)
Pain (1.1%)
Headache (3.4%)
Migraine (2.3%)
Dyspepsia (2.3%)
Gastrointestinal disorder (1.1%)
Nausea (3.4%)
Diarrhoea (1.1%)
Myalgia (1.1%)
Dizziness (1.1%)
Abnormal thinking (1.1%)
Sources:
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Other AEs: Abdominal pain, Back pain...
Other AEs:
Abdominal pain (4.6%)
Back pain (3.4%)
Headache (3.2%)
Nausea (2.3%)
Constipation (2.1%)
Abnormal liver function tests (7.5%)
ALT increased (3%)
CPK increased (3%)
AST increased (3.4%)
Respiratory disorder (6.2%)
Rhinitis (2.3%)
Urticaria (1.1%)
Rash (1.4%)
Sources:
200 mg 2 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
unhealthy
n = 46
Health Status: unhealthy
Condition: hyperlipoproteinaemia
Sex: M+F
Population Size: 46
Sources:
AEs

AEs

AESignificanceDosePopulation
Abnormal thinking 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Asthenia 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Diarrhoea 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Dizziness 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Gastrointestinal disorder 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Myalgia 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Pain 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Dyspepsia 2.3%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Migraine 2.3%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Headache 3.4%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Nausea 3.4%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Urticaria 1.1%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Rash 1.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Constipation 2.1%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Nausea 2.3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Rhinitis 2.3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
ALT increased 3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
CPK increased 3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Headache 3.2%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
AST increased 3.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Back pain 3.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Abdominal pain 4.6%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Respiratory disorder 6.2%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Abnormal liver function tests 7.5%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate
no
no
no
no
weak
weak
yes [IC50 170 uM]
yes [IC50 2.39 uM]
yes [IC50 5.83 uM]
yes [Inhibition 50 uM]
yes [Ki 105.2 uM]
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Advances in lipid-lowering therapy in atherosclerosis.
2001
[New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis].
2001
Fenofibrate raises plasma homocysteine levels in the fasted and fed states.
2001 Apr
Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat.
2001 Aug
PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells.
2001 Aug
Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
2001 Dec
Peroxisome proliferator-activated receptor a ligands increase lectin-like oxidized low density lipoprotein receptor-1 expression in vascular endothelial cells.
2001 Dec
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
2001 Dec
The transcription of the peroxisome proliferator-activated receptor alpha gene is regulated by protein kinase C.
2001 Dec 15
Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
2001 Dec 20
Rat adrenoleukodystrophy-related (ALDR) gene: full-length cDNA sequence and new insight in expression.
2001 Jan 26
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
2001 Jul
Fenofibrate and warfarin interaction.
2001 Jul
Fibrate-induced increase in blood urea and creatinine.
2001 Jul
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
2001 Jul 7
Effect of fenofibrate on fatty liver in rats treated with alcohol.
2001 Jun
Fibrate treatment can increase serum creatinine levels.
2001 Jun
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
2001 Jun
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
2001 Mar
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.
2001 Mar 24
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
2001 May 15
Choice of lipid-regulating drugs.
2001 May 28
Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.
2001 May 29
Comparison of DNA damage photoinduced by ketoprofen, fenofibric acid and benzophenone via electron and energy transfer.
2001 Nov
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
2001 Nov
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
2001 Nov 24
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
2001 Nov 24
Fibrates and homocysteine.
2001 Nov-Dec
[Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases].
2001 Oct
Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
2001 Oct
Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
2001 Oct
Fenofibrate: a new treatment for hyperuricaemia and gout?
2001 Oct
Regulation of lipid metabolism and gene expression by fenofibrate in hamsters.
2001 Oct 31
Cerivastatin and gemfibrozil-associated rhabdomyolysis.
2001 Sep
Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
2001 Sep
Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates.
2001 Sep
[Effect of phenofibrate treatment on endothelial dysfunction in patients with history of myocardial infarction in young age].
2002
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
2002 Apr 5
Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation.
2002 Apr 9
[Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
2002 Feb
Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
2002 Jan
Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.
2002 Jan
Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha.
2002 Jan
Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease.
2002 Jan 1
Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation.
2002 Mar
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
2002 Mar
Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
2002 Mar-Apr
Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha.
2002 May
Patents

Sample Use Guides

Primary Hypercholesterolemia or Mixed Hyperlipidemia: the initial dose of TRICOR (FENOFIBRATE TABLETS) is 145 mg per day Hypertriglyceridemia: the initial dose is 48 to 145 mg per day
Route of Administration: Oral
Fenofibrate may protect against endothelin-1 (ET-1)-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiachypertrophy and heart failure.
Name Type Language
FENOFIBRATE
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
FENOFIBRATE [MI]
Common Name English
ANTARA
Brand Name English
FENOFIBRATE [USAN]
Common Name English
FENOFIBRATE [EP MONOGRAPH]
Common Name English
LIPOFEN
Brand Name English
LIPANTIL
Brand Name English
FENOFIBRATE DELAYED RELEASE
Common Name English
TRIGLIDE
Brand Name English
FENOFIBRATE [USP MONOGRAPH]
Common Name English
FENOGLIDE
Brand Name English
FENOFIBRATE [VANDF]
Common Name English
FENOFIBRATE [MART.]
Common Name English
FENOFIBRATE [USP IMPURITY]
Common Name English
FENOFIBRATE [JAN]
Common Name English
FENOFIBRATE MICRONIZED
Common Name English
FENOFIBRATE [EMA EPAR]
Common Name English
FENOFIBRATE [USP-RS]
Common Name English
ISOPROPYL 2-(P-(P-CHLOROBENZOYL)PHENOXY)-2-METHYLPROPIONATE
Common Name English
Fenofibrate [WHO-DD]
Common Name English
LIPIDIL
Brand Name English
TRICOR
Brand Name English
FENOFIBRATE [HSDB]
Common Name English
FENOFIBRATE [ORANGE BOOK]
Common Name English
fenofibrate [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175375
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
WHO-VATC QC10BA03
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
WHO-ATC C10BA04
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
LIVERTOX NBK548607
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
NCI_THESAURUS C98150
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
WHO-VATC QC10AB05
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
WHO-ATC C10BA03
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
WHO-ATC C10AB05
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
WHO-VATC QC10BA04
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
NDF-RT N0000170118
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
NDF-RT N0000175596
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
NDF-RT N0000170118
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
Code System Code Type Description
INN
3996
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
DAILYMED
U202363UOS
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
EVMPD
SUB07576MIG
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
IUPHAR
7186
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
HSDB
7736
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
NCI_THESAURUS
C29047
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
CAS
49562-28-9
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
ChEMBL
CHEMBL672
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
RXCUI
221100
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
DRUG BANK
DB01039
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
FDA UNII
U202363UOS
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
ECHA (EC/EINECS)
256-376-3
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
CHEBI
5001
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
LACTMED
Fenofibrate
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
RS_ITEM_NUM
1269447
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
MESH
D011345
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
DRUG CENTRAL
1152
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
RXCUI
8703
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
ALTERNATIVE
WIKIPEDIA
FENOFIBRATE
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
MERCK INDEX
m5279
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID2029874
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
PUBCHEM
3339
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
SMS_ID
100000092530
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY